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One well-documented method to control im-
munity and tolerance is through the regulation 
of nutrients in their immune microenvironment. 
Best described is the tryptophan deficiency 
mediated by the catabolic enzyme indoleamine 
2,3-dioxygenase (IDO), which locally depletes 
tryptophan and liberates the immunoregulatory 
metabolites known as kynurenines. T cell acti-
vation is exquisitely sensitive to local tryptophan 
catabolism, and thus this enzyme exerts profound 
protective effects in allo-fetal rejection, auto-
immunity, and inflammation. IDO can also be 
detected in tumors and draining LNs, and DC 
expression of IDO limits T cell responsiveness to 
antigen (Munn and Mellor, 2007; Katz et al., 
2008). In addition to IDO, some human cancers 
express tryptophan 2,3-dioxygenase (TDO), 
which also utilizes tryptophan as a substrate to 
produce kynurenines (Pilotte et al., 2012). Fur-
thermore, cysteine and arginine deficiency in 
tumors can inhibit T cell activation (Rodriguez 
et al., 2004; Srivastava et al., 2010), suggesting 
that loss of any number of amino acids may 
serve as a common tumor escape mechanism.
In accordance with these findings, in a model 
of skin allograft tolerance, it was observed that 
multiple catabolic enzymes were up-regulated 
that consume a litany of essential amino acids. 
It was shown that these enzymatic activities could 
dampen T cell proliferation through nutrient 
deprivation (Cobbold et al., 2009). One of the 
many enzymes that were up-regulated was 
Tph-1 (tryptophan hydroxylase-1), a synthase 
which utilizes tryptophan as a substrate to pro-
duce serotonin and melatonin (Yao et al., 2011), 
and it was speculated that Tph-1 may precipi-
tate the loss of tryptophan in the local micro-
environment (Zelenika et al., 2001). In the 
present study, we sought to determine whether 
Tph-1, the isoform expressed in the periphery 
(Walther et al., 2003), could function as a 
regulator of immunity through the control of 
tryptophan metabolism and uncovered a novel 
and profound immunoregulatory function for 
this enzyme.
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Tryptophan hydroxylase-1 regulates immune 
tolerance and inflammation
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Nutrient deprivation based on the loss of essential amino acids by catabolic enzymes in the 
microenvironment is a critical means to control inflammatory responses and immune tolerance. 
Here we report the novel finding that Tph-1 (tryptophan hydroxylase-1), a synthase which 
catalyses the conversion of tryptophan to serotonin and exhausts tryptophan, is a potent 
regulator of immunity. In models of skin allograft tolerance, tumor growth, and experimental 
autoimmune encephalomyelitis, Tph-1 deficiency breaks allograft tolerance, induces tumor 
remission, and intensifies neuroinflammation, respectively. All of these effects of Tph-1 
deficiency are independent of its downstream product serotonin. Because mast cells (MCs) 
appear to be the major source of Tph-1 and restoration of Tph-1 in the MC compartment 
in vivo compensates for the defect, these experiments introduce a fundamentally new mecha-
nism of MC-mediated immune suppression that broadly impacts multiple arms of immunity.
© 2012 Nowak et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
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RESULTS
Mast cells (MCs) express Tph-1
A study from our laboratory previously reported that MCs 
are critical in maintaining regulatory T cell–dependent skin 
allograft tolerance (Lu et al., 2006). Concordant with these 
observations, gene array analyses performed by two differ-
ent groups established that tolerant skin allografts display 
an MC signature with heightened signal for Tph-1 and 
other MC gene products (Zelenika et al., 2001; Lu et al., 
2006). Pilot experiments showed that purified MCs from 
tolerant allografts expressed heightened levels of Tph-1 
compared with MCs from syngeneic grafts (not depicted). 
It was also observed that peritoneal MCs from naive mice 
express 1,000-fold higher expression for Tph-1 message 
than any other hematopoietic cell type examined by quan-
titative RT-PCR (qRT-PCR) and that Tph protein 
expression appears to be restricted to MCs (Fig. 1). Height-
ened Tph-1 expression in MCs appeared unique, as the 
expression for other catabolic enzymes was absent or min-
imal (Fig. 1 B).
Figure 1. MCs have specific expression of Tph-1. (A) Tph-1 expression (as determined by qRT-PCR) of the indicated cell types standardized 
to -actin expression (mean ± SEM) is shown. For each cell type, two independent FACS-sorted samples were used. Each MC and macrophage sample 
was pooled from the peritoneal lavage of 20 mice. All other samples were pooled from the LN and spleen of two to four mice. (B) Peritoneal MC expres-
sion of the following genes was determined by qRT-PCR: arginase (Arg), dopa decarboxylase (Ddc), histidine decarboxylase (Hdc), IDO, inducible nitric oxide 
synthase (iNos), l-threonine dehydrogenase (Tdh), TDO, Tph-1, and Tph-2. Two independent samples were used to determine mean ± SEM shown. 
(A and B) ND indicates that a signal was not detected. (C) Intracellular staining for Tph-1 was performed for MCs, CD4+ T cells, CD8+ T cells, B cells, 
CD11chi DCs, and F4/80+ CD11b+ macrophages in WT (bold lines) and Tph-1/ (shaded areas) mice (n = 3–4 mice/group, and each cell type was tested in 
at least two independent experiments). (D) Naive LN sections were sectioned and stained for Tph-1 expression on MCs. CD117 staining is blue, Tph-1 
staining is green, and overlap is white. Results are representative of three different mice/group. Bar, 10 µm.
Figure 2. Tph-1/ mice have elevated serum tryptophan levels 
and a normal MC compartment. (A) Serum tryptophan levels from  
in-house-bred naive WT and Tph-1/ mice (n = 13–14 mice/group from 
three independent experiments) were determined by ELISA. Mean ± SEM 
is shown. The p-value was determined by Student’s t test. (B) Peritoneal 
lavage, lungs, intestines, spleen, and skin of Tph-1/ mice were analyzed 
by flow cytometry for the relative number of MCs and compared with WT 
mice. Data are pooled from two independent experiments (n = 7–8 mice/
group), and mean is indicated.
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levels of tryptophan are generally attributed to the activ-
ity of TDO, it appears that IDO can modulate the relative 
amounts of tryptophan under inflammatory conditions 
(Schröcksnadel et al., 2006). Therefore, it appears that con-
stitutive loss of Tph-1 can also alter tryptophan levels in the 
periphery. The analysis of immune cell phenotypes on WT 
and Tph-1/ mice revealed that these mice were indistin-
guishable across all tissues examined (not depicted). Fur-
thermore, the lack of Tph-1 does not appear to impact the 
frequency (Fig. 2 B) or numbers (not depicted) of MCs, 
which have been described as the cells most abundantly 
expressing Tph-1 (Stoll et al., 1990; Mathiau et al., 1994; 
Csaba et al., 2006).
Based on these findings and the recognition that Tph-1 
can locally deplete tryptophan, the potential functional in-
volvement of Tph-1 in mediating immune tolerance within 
the skin microenvironment was studied in Tph-1/ mice. 
Tph-1/ mice have been previously described as harbor-
ing no gross physical abnormalities except diminished cardiac 
function (Côté et al., 2003) and enhanced liver microcircu-
lation (Lang et al., 2008). However, the immune compart-
ments of Tph-1/ mice have not been well characterized. 
The genetic absence of Tph-1 appears to impact the steady-
state levels of tryptophan as serum from Tph-1/ mice 
contains 5 µg/ml more tryptophan in serum than that of 
WT controls (P = 0.0152; Fig. 2 A). Although systemic 
Figure 3. Tph-1 is essential for the maintenance of tolerance. (A and B) WT and Tph-1/ mice were grafted with syngeneic C57BL/6 or allogeneic 
CB6F1 skin. DST- and -CD40L–treated mice received an allogeneic skin graft. In the indicated groups, PCPA and 5-HTP were given every other day for the 
duration of the experiment starting at day 8 for DST/-CD40L–treated mice and day 1 for syngeneic and allogeneic mice. The number of mice/group 
is indicated, and data were pooled from two or more independent experiments. (C) Histology staining on skin allografts in DST/-CD40L–treated mice  
of Tph-1 or WT mice at day 10 after grafting. Tph-1 is shown in red, and cKit (CD117) is shown in blue. In the overlay, white arrows indicated double-
positive cells, and blue arrows indicate cells positive for cKit but not for Tph-1. (D) Reconstitution of serotonin in the granules of MCs was confirmed by 
immunofluorescent staining on purified peritoneal lavage MCs. Serotonin staining is in red, cKit staining in blue, and nuclear staining in yellow. The  
white arrows indicate MCs positive for serotonin, whereas the red arrows indicate MCs negative for serotonin. Bars, 20 µm. (E) Graft draining LNs from  
DST/-CD40L–treated mice were depleted of antigen-presenting cells and restimulated with irradiated WT of F1 antigen-presenting cells for 18 h for IFN- 
and for 36 h for IL-17A before ELISPOT development. Data show n = 7–8 mice/group, and mean ± SEM is representative of results from two independent 
experiments. P-values were determined by Student’s t test. (F) Mast-deficient (Wsh) mice were locally (skin) reconstituted with 6–8-wk-old MCs from WT 
or Tph-1/ mice 8 wk before DST/-CD40L treatment. After receiving a skin graft, mice were monitored for rejection for another 50 d. Data shown were 
combined from two independent experiments.
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Wsh mice were reconstituted with WT or Tph-1/ BM-derived 
MCs (BMMCs). As previously reported, DST/-CD40L–
treated Wsh mice reconstituted with WT BMMCs show a 
gradual erosion of tolerance leading to rejection of 50% 
of the allografts between days 30 and 60 after transplantation 
(Lu et al., 2006). However, when DST/-CD40L–treated 
Donor-specific transfusion (DST)/-CD40L–treated mice 
reject allogeneic skin grafts with Tph-1 deficiency
The potential role of Tph-1 deficiency in immune tolerance 
was studied in a model of skin allograft tolerance. Here mice 
were treated with a tolerance-inducing regimen of DST in 
combination with -CD40L on days 7, 5, and 3 and 
then received an allogeneic CB6F1 (C57BL/6 × BALB/c) 
skin graft on day 0 (Quezada et al., 2003). In the first experi-
ments, the specific and irreversible inhibitor parachlorophe-
nylalanine (PCPA), which has been reported to effectively 
block the effects of Tph with multiple treatments (Côté et al., 
2003), was used. Approximately 90% of the PCPA-treated 
mice receiving DST/-CD40L rejected their skin allografts 
within 30 d. In contrast, 100% of DST/-CD40L–treated 
WT mice retained their skin allografts for >50 d (Fig. 3 A). 
The role of Tph-1 in allograft tolerance was then studied in 
Tph-1/ mice (Fig. 3, A and B). It was shown that 80% of 
the DST/-CD40L–treated Tph-1/ mice rejected their 
skin grafts within 30 d as compared with DST/-CD40L–
treated WT mice (P < 0.0001 between these two groups by 
log-rank test). Tph-1/ mice grafted with syngeneic grafts 
retained those grafts as did WT controls, establishing that 
Tph-1 is not involved in wound healing. Furthermore, allo-
geneic grafts placed on unmanipulated WT or Tph-1/ 
mice mounted similar rejection responses with regard to the 
frequency and rates of graft rejection (Fig. 3 B). It was also 
noted that the majority of MCs in Tph-1/ mice in donor 
skin allografts were negative for Tph-1, indicating that they 
were host derived (Fig. 3 C). The loss of tolerance in this 
model was not caused by the absence of peripheral serotonin 
synthesis in the Tph-1/ mice as adding back 5-hydroxy-
tryptophan (5-HTP), which bypasses the Tph-1 deficiency to 
restore serotonin levels, did not allow for long-lived toler-
ance in Tph-1/ mice (Fig. 3 B). Because MCs store serotonin 
in their granules, reconstitution of serotonin biosynthesis 
by 5-HTP administration in Tph-1/ mice was confirmed 
by histological analysis of cytospins of peritoneal lavage 
MCs (Fig. 3 D). It is therefore concluded that Tph-1 is re-
quired for the maintenance of peripheral tolerance indepen-
dently of serotonin.
To determine whether rejection in the DST/-CD40L–
treated Tph-1/ mice was caused by the emergence of an 
allogeneic T cell response, T cells from draining LNs 14 d after 
the initial grafting were recalled with F1 antigen-presenting 
cells to assess their cytokine production (Fig. 3 E). An increase 
in the allogeneic-specific IFN- response (P = 0.0334) as 
well as IL-17A response (P = 0.0084) was observed in the 
DST/-CD40L–treated Tph-1/ mice compared with 
similarly prepared WT mice.
Based on the finding that the highest signal of Tph-1 mes-
sage and protein expression occurs in MCs, it was envisioned 
that MC-derived Tph-1 is responsible for the phenotype seen 
in the deficient mice. Wsh mice harbor a MC deficiency caused 
by a c-Kit mutation and can be readily reconstituted with ge-
netically deficient MCs to test the role of MC-derived genes 
in immune responses (Grimbaldeston et al., 2005). As such, 
Figure 4. Tph-1 is essential for the generation of protective  
T cell–mediated antitumor immunity. (A) MB49 was inoculated, and 
tumor growth was monitored over time in all the groups. One group  
received 5-HTP every other day from the day before the start of experi-
ment. Data show mean ± SEM of n = 6–8 mice/group and are representa-
tive of results from three independent experiments. P-values listed are for 
the group they are shown next to in comparison with WT female mice 
and were determined by two-way ANOVA. (B) On day 11 after tumor  
inoculation, whole tumor draining LNs were isolated, plated, and restimu-
lated with irradiated tumor to determine IFN- ELISPOTS after 18 h and 
IL-17A ELISPOTS after 36 h, restimulated for 18 and 36 h, respectively. 
Data show mean ± SEM for n = 10–16 mice/group and were pooled from 
three independent experiments. The p-value shown was determined for 
the indicated groups by Tukey posttest after one-way ANOVA analysis.  
(C) MB49 was inoculated systemically through the tail vein in age-
matched female WT and Tph-1/ mice as well as female Wsh mice  
systemically reconstituted with BMMCs from WT and Tph-1/ mice.  
The graph is compiled from three independent experiments with total 
numbers of mice indicated in the figure. The p-value was determined by 
log-rank comparison between the two BMMC-reconstituted groups.
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Tph-1 deficiency exacerbates experimental  
autoimmune encephalomyelitis (EAE)
The question arose as to whether Tph-1 only enhances 
immunity under immune-tolerant or -suppressive conditions, 
or can it function in tempering inflammation in general? To 
address this question, the impact of Tph-1 deficiency on a 
central nervous system (CNS) inflammatory disease was studied. 
EAE is a model of CNS inflammation in which encephalito-
genic Th17 lineage T cells infiltrate the CNS, mediate dam-
age, and cause ascending paralysis. Using suboptimal disease 
conditions, it was found that Tph-1/ mice develop earlier 
and more severe disease than controls (P = 0.0064; Fig. 5 A). 
As seen in all other models tested, restoration of serotonin 
levels by administration of 5-HTP had no effect on the im-
munological impact of Tph-1 deficiency. In this specific case, 
it was shown that serotonin levels in serum were restored 
to the same levels of controls after just one injection with 
5-HTP (Fig. 5 B). Furthermore, long-term treatment of 
5-HTP restored serotonin to a level greater than WT con-
trols (P < 0.001; Fig. 5 C). The finding that serotonin is not 
involved is also supported by the observation that serotonin 
transporter–deficient mice have attenuated EAE (Hofstetter 
et al., 2005).
Further characterization of immune responses during 
EAE found that Tph-1/ mice have an enhanced frequency 
of encephalitogenic T cells. Analysis of T cell responses dur-
ing EAE revealed that on day 7 after immunization (when nei-
ther group showed disease), Tph-1/ mice had greater numbers 
of CD4+ T cells expressing CCR6 (P = 0.0484), one of the 
adhesion molecules necessary to be on the first wave of T cells 
that infiltrate the CNS (Fig. 6 A; Liston et al., 2009; Reboldi 
et al., 2009). Tph-1/ mice also had elevated recall IL-17A 
production by CD4+ T cells (P = 0.0002). At late stages of 
disease, Tph-1/ mice also had elevated numbers of CD4+ 
and CD8+ T cells that were infiltrating the CNS, which have 
high IL-17A and IFN- recall responses (Fig. 6 B). To deter-
mine whether this effect is just caused by differences in T cell 
Wsh mice were reconstituted with Tph-1/ BMMCs, it was 
observed that all mice rejected their allograft within 30 d with 
P = 0.0002 in comparison with WT BMMC-reconstituted 
mice by log-rank test (Fig. 3 F). Therefore, it appears that 
MC-derived Tph-1, and not Tph-1 produced by other cells, 
is necessary for long-term graft tolerance.
Tph-1 and immune suppression to tumor
As MC expression of Tph-1 is critical for allograft tolerance 
and MCs have been implicated in suppressing antitumor 
immunity (Maltby et al., 2009), experiments were designed 
to determine whether MC-derived Tph-1 mediated immune 
tolerance to an intradermal (i.d.) skin tumor model. MB49 
is a bladder cell carcinoma that expresses male minor histo-
compatibility antigen and readily grows and kills male mice 
because they are centrally tolerant to H-Y (Summerhayes and 
Franks, 1979; Halak et al., 1999). In contrast, female WT mice 
have delayed tumor growth kinetics in comparison with WT 
males yet nonetheless ultimately succumb to tumor. Strikingly, 
female Tph-1/ mice have reduced tumor growth kinetics, 
and 50% completely reject MB49. It was also confirmed 
that the effect of Tph-1 deficiency was independent of sero-
tonin biosynthesis by the lack of effect of administration of 
5-HTP (Fig. 4 A). 11 d after tumor inoculation, tumor-specific 
recall responses from T cells from the draining LNs were 
measured (Fig. 4 B). Female Tph-1/ mice had significantly 
higher numbers of IL-17A–specific spots (P < 0.01) in com-
parison with all other groups, and IFN-–specific spots were 
elevated in female Tph-1/ mice although it did not reach 
statistical significance. Through reconstitution of Wsh mice 
with either BMMCs from either WT or Tph-1/ mice, it 
was confirmed that Tph-1/ BMMCs conferred protection 
to the same extent as female Tph-1/ mice with P = 0.0052 
between WT and Tph-1/ BMMC-reconstituted mice 
(Fig. 4 C). The data establish that MCs maintain a suppressive 
antitumor microenvironment and that Tph-1 is a major 
mediator within this context.
Figure 5. Tph-1/ mice have exacer-
bated EAE independent of their serotonin 
level. (A) WT, Tph-1/, and Tph-1/ + 5-HTP–
treated (starting on day 1 and continuing 
every other day for the duration of the experi-
ment) mice were monitored and scored. Data 
are pooled from three independent experi-
ments and show mean ± SEM for n = 13 
mice/group. P-values indicate significance  
in comparison with WT mice and were calcu-
lated by Mann–Whitney U test. (B) Serum 
serotonin levels of WT, Tph-1/, and Tph-1/ + 
5-HTP–treated (one shot 2 d prior) mice on 
day 1 after EAE induction were determined by 
ELISA (n = 11–12 mice/group pooled from 
three independent experiments). (C) Serum 
serotonin levels of WT, Tph-1/, and Tph-1/ + 5-HTP–treated (last shot given 2 d before sample collection) mice on day 21 after EAE induction were 
determined by ELISA (n = 13 mice/group pooled from three independent experiments). The p-value was determined by one-way ANOVA analysis and indi-
cates difference from WT mice. (B and C) Mean ± SEM is shown.
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(Cobbold et al., 2009). Therefore, it presented itself as a 
potential target for mediating the differences observed in 
WT and Tph-1/ mice. The phosphorylation of S6 ribo-
protein, one of the targets of mTOR, in CD4+ T cells was 
measured in the draining LNs 4 d after EAE immunization, 
and we found that it was elevated in Tph-1/ mice (P = 
0.04; Fig. 7). This suggests that comparatively there is a 
reduction of mTOR activity in WT mice that is consistent 
with there potentially being a tryptophan-deficient micro-
environment imposed by Tph-1.
DISCUSSION
The findings presented herein describe Tph-1 as an impor-
tant and novel MC-derived regulator of immunological tol-
erance. This single molecule exerts striking alterations in 
immunological outcomes in models of transplantation toler-
ance, tumor growth, and autoimmunity. Tph-1 metabolizes 
priming, myelin-specific Th17 cells were adoptively trans-
ferred into WT and Tph-1/ mice. Data show that these 
T cells could effectively initiate disease in Tph-1/ mice 
but not controls (P < 0.0001), showing that Tph-1/ mice 
are better able to sustain and facilitate encephalitogenic 
T cell–mediated pathogenesis (Fig. 6 C). Although hampered 
by differences in EAE severity caused by the increased age 
of the mice, the phenotype of Wsh mice reconstituted with 
Tph-1/ BMMCs looked consistent with that of Tph-1/ 
mice, suggesting MC-derived Tph-1 is responsible for this 
effect (Fig. 6 D).
Tph-1/ mice have enhanced signaling  
of mammalian target of rapamycin (mTOR)
The mTOR pathway can promote CD4 T cell differentiation 
to Th1 and Th17 cells (Delgoffe et al., 2009), and its activ-
ity is inhibited in vitro with loss of essential amino acids 
Figure 6. Tph-1/ mice have increased encephalitogenic T cell responses. (A) Day 7 after inoculation for EAE, mice were taken down and draining 
LNs were stained for the indicated parameters (after restimulation for cytokine stains). Data are pooled from three independent experiments (n = 11 
mice/group), and mean is indicated. (B) Day 21 after inoculation, lymphocytes from the CNS were isolated and stained for the indicated parameters  
(after restimulation for cytokine stains). Data are pooled from three independent experiments (n = 15–18 mice/group), and mean is indicated.  
(A and B) P-values were determined by Student’s t test. (C) Mice were injected with activated MOG35–55-specific T cells, and disease severity was moni-
tored over time. Data are pooled from two independent experiments and show mean ± SEM for n = 14–16 mice/group. The p-value was determined by  
Mann–Whitney U test. (D) Wsh mice were given WT or Tph-1/ BMMCs systemically and given 8 wk to reconstitute. These mice and age-matched con-
trols were immunized for active EAE and monitored for disease severity over time. Data show mean ± SEM for n = 10–15 mice/group pooled from two 
independent experiments.
JEM Vol. 209, No. 11 
Article
2133
(O’Connell et al., 2006; Nakamura et al., 2008). It has 
also been observed in Tph-1/ mice that there is an 
enhanced ability to clear lymphocytic choriomeningitis 
virus (Lang et al., 2008) and reject the MC-38 colon 
cancer line (Nocito et al., 2008). However, in these cases, 
this is dependent on the loss of serotonin in these mice. 
Therefore, Tph-1 likely regulates immunity by regulating 
serotonin levels or by exhausting tryptophan depending on 
the nature of the immune response invoked. Certainly, the 
fact that Tph-1 can so profoundly impact tolerance and in-
flammation provides compelling incentive to consider Tph-1 
as a novel target in immune intervention.
MATERIALS AND METHODS
Mice. Tph-1/ mice fully backcrossed to a C57BL/6 background were 
provided by N. Horseman (University of Cincinnati, Cincinnati, OH) and 
maintained at the Dartmouth College animal facility. Male and female 6–8-
wk-old C57BL/6 mice were bred in-house for measurement of tryptophan 
in serum, all EAE experiments, and all ELISPOT experiments. In all other 
experiments, C57BL/6 mice were purchased from the National Cancer 
Institute. 2D2 TCR transgenic mice were provided by V. Kuchroo (Harvard 
University, Cambridge, MA) and maintained in-house. C57BL/6 KitW-sh 
(Wsh) mice were purchased from the Jackson Laboratory. CB6F1 (C57BL/6 × 
BALB/c hybrid) were purchased from the National Cancer Institute. Experi-
ments were performed under protocols approval by the Institutional Animal 
Care and Use Committee of Dartmouth College, and mice were maintained 
in a specific pathogen–free facility at Dartmouth Medical School.
MC reconstitution. BMMCs for MC reconstitution were generated by 
culturing BM cells with 20 ng/ml IL-3 (PeproTech) and 50 ng/ml stem cell 
factor (SCF; PeproTech) for 5–8 wk as shown previously (Lu et al., 2006). 
Purity was assessed by anti-CD117 and anti-FCRI staining on BMMC 
cultures (Lu et al., 2006). A total of 4–5 × 106 BMMCs were then injected 
i.d., i.v., and i.p. into Wsh recipients. Mice were allowed to rest for 8–12 wk 
before use in experiments. At the end of the experiment, reconstitution was 
confirmed by flow cytometry or histology.
Skin grafting. Skin grafting was performed as previously described (Markees 
et al., 1998). In brief, 1-cm2 full-thickness tail skins were collected from 
CB6F1 allogeneic donor or C57BL/6 syngenic donor mice. Skins were then 
stored on PBS-soaked gauze and were on the following day applied to the 
dorsal surface of age-matched WT or Tph-1/ host mice. Indicated groups 
were treated 7 d before grafting, via the i.v. injection of 3 × 107 DST in con-
junction with an injection of 250 µg anti-CD40L (clone MR1), followed by 
further injections on days 5 and 3 before graft. This regimen results in 
long-term tolerization of the mice to alloantigen.
Cell culture, tumor challenge, and vaccination. Murine bladder carci-
noma cell line MB49 was maintained in complete medium (RPMI 1640 
containing 10% fetal calf serum, 100 U/ml penicillin, 100 µg/ml streptomy-
cin, 2 mM glutamine, and 50 µM 2-mercaptoethanol). Mice were injected 
with 2.5 × 105 MB49 tumor cells i.d. on the right flank, and tumor diameters 
were measured with a caliper thrice weekly. Alternatively, mice were chal-
lenged with 2.5 × 105 MB49 tumor cells i.v. in the tail vein and were moni-
tored for survival.
tryptophan for the purpose of producing serotonin. How-
ever, the experiments presented here clearly show that the 
major immunological impact of this pathway is not through 
the regulation of serotonin levels and therefore must be 
caused by its ability to exhaust tryptophan as suggested by the 
mTOR experiments.
There are several catabolic enzymes that have been sug-
gested to contribute to the establishment of immune tolerance. 
For example, during skin allograft tolerance, DCs activated 
by regulatory T cells can express enzymes to consume 9 of the 
10 essential amino acids and cause a reduction in mTOR sig-
naling (Cobbold et al., 2009). Extensive work on IDO, one 
of the tryptophan-catabolizing enzymes, also shows that it 
can limit immune responses through the induction of the 
GCN2 stress response, which promotes anergy, as well as the 
production of tryptophan metabolites that suppress inflam-
mation (Munn and Mellor, 2007). There are also some indi-
cations that different catabolic enzymes may counter-regulate 
the activity of each other. For example, the production of nitric 
oxide by inducible nitric oxide synthase can prevent IDO ac-
tivity (Katz et al., 2008). However, in the case of Tph-1 ex-
pression by MCs, this does not appear to be occurring because 
MCs have little to no messenger RNA expression for other 
catabolic enzymes, so competition for substrate is not likely 
contributing to the immunosuppressive activity of Tph-1.
In the case of Tph-1, the question arises as to which cell 
type is the target of the tryptophan deficiency in the tolerant 
microenvironment. Although we observe enhancement of 
mTOR activity in CD4 T cells with Tph-1 deficiency during 
EAE, it is not yet clear whether this is the case in our trans-
plant and tumor models. In addition, there could be additional 
targets of Tph-1 activity. For example, we have recently re-
ported that within the tolerant allograft, graft-derived DCs 
mediate regional allo-specific unresponsiveness. Upon analysis 
of gene expression of these DCs, it appears that they have 
experienced a nutrient-stressed environment (de Vries et al., 
2011). We would contend that this is caused by Tph-1 activi-
ties on DCs from the increased MCs that infiltrate the tolerant 
allograft. It would also be of interest to determine the factors 
that up-regulate Tph-1 expression in MCs as well as addi-
tional cell types to potentially mediate immune tolerance.
The experiments presented provide a new prospective 
on this immunologically important enzyme. Its end product 
serotonin can impact inflammation, particularly in the gut 
Figure 7. Tph-1/ mice have enhanced mTOR activity. 
(A) Example staining of P-S6 and its isotype control antibody is 
shown. (B) Day 4 after inoculation for EAE, mice were taken 
down, draining LNs were harvested, and CD4+ T cells were stained 
for P-S6 expression (and isotype control). Data are pooled from 
three independent experiments with n = 15 mice/group. Mean is 
indicated, and the p-value was determined by Student’s t test.
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(Becher et al., 2002). All samples were standardized to expression of -actin. 
Primers used are as follows: -actin (5-CCACACCCGCCAGTTCG-3 
and 5-TCTGGGCCTCGTCACCCACAT-3), Tph-1 (5-GAAGAC-
AACATCCCGCAACT-3 and 5-GTTCAGCCAAGAGAGGAACG-3), 
arginase (5-CAGAAGAATGGAAGAGTCAG-3 and 5-CAGATATG-
CAGGGAGTCACC-3), dopa decarboxylase (5-AGGGCAGAGAAAGAA-
TGAAAGCA-3 and 5-GGAGTGGTAGTTATTTTTCTCTTTCCA-3), 
histidine decarboxylase (5-GATCAGATTTCTACCTGTGG-3 and 
5-GTGTACCATCATCCACTTGG-3), IDO (5-TGGCAAACTGGA-
AGAAAAAG-3 and 5-ATTGCTTTCAGGTCTTGACG-3), inducible 
nitric oxide synthase (5-ACCCCTGTGTTCCACCAGGAGATGTT-3 and 
5-TGAAGCCATGACCTTTCGCATTAGCA-3), l-threonine dehydrog-
enase (5-AAGCACGCGCCTGACTTC-3 and 5-CCGAGCATTG-
CTGTCATCTAGA-3), TDO (5-TGGGAACTAGATTCTGTTCG-3 and 
5-TCGCTGCTGAAGTAAGAGCT-3), and Tph-2 (5-CAGGAGAGGG-
TTGTCCTTGG-3 and 5-TTTGCCGCTTTTCTTGTCCT-3).
Statistical analysis. Data graphs were made using Prism software (GraphPad 
Software) and expressed as the mean ± SEM. Differences for graphs with 
one grouping variables were analyzed by Student’s t test (two groups) or 
one-way analysis of variance (ANOVA) and Tukey analysis (three or more 
groups). Log-rank tests were used to compare skin graft survival and survival 
of mice inoculated with MB49. For the study of MB49 growth kinetics, 
two-way ANOVA was used to assess significance. In EAE time course experi-
ments, statistical relevance was determined using Mann–Whitney U Test.
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